An Open, Randomized, Parallel-Group Study to Compare the Efficacy and Safety Profile of Inhaled Human Insulin (Exubera) With Glibenclamide as Adjunctive Therapy in Patients With Type 2 Diabetes Poorly Controlled on Metformin
Response to Kanna and Abreu-Pacheco
- Anthony H. Barnett, BSC, MD, FRCP1,
- Manfred Dreyer, MD2,
- Peter Lange, MD3,
- Marjana Serdarevic-Pehar4 and
- on behalf of the Exubera Phase III Study Group
- 1University of Birmingham and Heart of England National Health Service Foundation Trust (Teaching), Birmingham, U.K
- 2Department of Diabetes and Metabolism, Bethanien Krankenhaus, Hamburg, Germany
- 3Department of Respiratory Medicine, Hvidovre University Hospital, Hvidovre, Denmark
- 4Pfizer Ltd., Sandwich, U.K
- Address correspondence to A.H. Barnett, Undergraduate Centre, Birmingham Heartlands Hospital, Bordesley Green East, Birmingham, B9 5SS, U.K. E-mail: anthony.barnett{at}heartofengland.nhs.uk
We thank Kanna and Abreu-Pacheco (1) for their comments on our study (2). As Kanna and Abreu-Pacheco point out, overweight and obesity are strongly linked to the development of type 2 diabetes and can complicate its management. While most patients with type 2 diabetes are overweight (3), this study (2) included individuals with a range of BMI values typical of those seen in clinical practice; mean BMI in …
